LYT-200 + decitabine

LYT-200 + decitabine is an investigational combination therapy for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). LYT-200 is a fully human IgG4 monoclonal antibody targeting galectin-9, an immunosuppressive and oncogenic protein, implicated in leukemia and other tumors. LYT-200 exerts its anti-leukemic effect by inducing apoptosis and DNA damage, downregulating galectin-9, and activating NK and T cells. Decitabine is a small molecule hypomethylating agent that acts as a DNA methyltransferase inhibitor, reactivating silenced genes involved in tumor suppression and differentiation. The combination is administered via intravenous infusion for LYT-200 (weekly) and decitabine (IV, 5 days/cycle) and is under phase 1 evaluation for safety, tolerability, pharmacokinetics, and preliminary efficacy in heavily pretreated relapsed/refractory AML and high-risk MDS patients[1][2][3][4][5].